Phase 3
Completed N=178
An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
Source: ClinicalTrials.gov NCT05393895 ↗Enrolled (actual)
178
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcomePrimary: Number of Participants With Treatment Emergent Adverse Events. — 43; 16 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment Emergent Adverse Events. |
43; 16 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects must have presbyopia
Exclusion Criteria
- Have any contraindications to the study medications or diagnoses that would confound the study data
Data sourced from ClinicalTrials.gov (NCT05393895). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.